Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Office Of Criminal Investigations May Undergo Overhaul With The Resignation of Its Director

This article was originally published in The Pink Sheet Daily

Executive Summary

Terry Vermillion, who has headed up the office for 18 years, resigned two months after a whistleblower complaint about him was made public.

You may also be interested in...



FDA Investigators Search For Silver Bullets In Off-Label Probes

OCI Director John Roth set to depart upon his confirmation to Homeland Security Department post.

FDA's New ORA Head, Dara Corrigan, Has Broad Enforcement Experience

Former acting HHS inspector general will become associate commissioner for regulatory affairs two years after Margaret O'Keeffe Glavin's retirement.

Hamburg Outlines Planned Reforms Of FDA Criminal Investigations Office

FDA Commissioner Margaret Hamburg outlined reforms planned for the agency's Office of Criminal Investigations, including new criteria for selecting misdemeanor prosecution cases against responsible corporate officials

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel